Cellectis S.A. (CLLS) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Stablecoin Development (SDEV) has outperformed Cellectis S.A. (CLLS) over the past year, losing 55.9% versus a loss of 64.9%. Over five years, CLLS leads with a -87.6% price change compared with -99.9% for SDEV. Stablecoin Development is the larger company by market cap ($143.9 million vs $135.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | SDEV |
|---|---|---|
| Share price | $1.34 | $2.78 |
| Market cap | $134.96M | $143.87M |
| 1-day change | -4.29% | -14.46% |
| YTD return | -72.31% | -90.14% |
| 1-year return | -64.92% | -55.87% |
| 5-year return | -87.63% | -99.92% |
| EPS (TTM) | $-0.64 | $-18.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $99.75 |
| 52-week low | $1.25 | $0.78 |
| Distance from 52-week high | -75.55% | -97.21% |
| Analyst consensus | none | — |
| Avg. price target upside | +297.76% | — |
| Average volume | 78.85K | 11.20M |
| Shares outstanding | 72.72M | 51.75M |
| Employees | 224 | 2 |
| Sector | Healthcare | Financial Services |
| Industry | Biotechnology | Asset Management |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Cellectis S.A. in Healthcare and Stablecoin Development in Financial Services.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Healthcare · Biotechnology · 224 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Financial Services · Asset Management · 2 employees
CLLS vs SDEV FAQ
Which is bigger, Cellectis S.A. or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $143.87M compared with $134.96M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or SDEV?
SDEV returned -55.87% over the past 12 months, compared with -64.92% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Stablecoin Development in the same industry?
No. Cellectis S.A. is in the Healthcare sector, while Stablecoin Development is in Financial Services.